There is plenty of discussion that can be had when referring to the condition known as glioblastoma. Viewed as the very condition that took the life of Senator Edward Kennedy a few years ago, it is seen as the most aggressive and common condition in the brain. As a result, therapies are built and drugs are tested in order to see which of these can yield the greatest of the results. After reading about the inclusion of HSPPC-96, I think that there is even more discussion that can be made by Stuart Millheiser and others.
News-Medical posted an article that spoke about an experimental vaccine that could be used in order to help those who have this condition. It would entail a degree of tumor tissue, which is needed in order to make it impactful. As the article would go on to state, patients saw increased levels of survival in comparison to what they might have had with only standard methods of care. There is quite a bit to talk about when it comes to the phase 2 trial tied to this vaccine.
For those who are unfamiliar with glioblastoma, you may be curious as to what makes it so aggressive? The article said that the tumors progress at rapid paces and, because of this, treatment options have limited results. Of course, there are methods that can be taken up, the most common being standard invasive surgery followed by chemotherapy and radiation. However, the long-term results are hard to document, which can be said about conditions like ALS too. This means that more work will be done, as well as seen by the likes of Stuart Millheiser.
The phase 2 trial came into being and it included a total of 41 patients that had tumors in between 2007 and 2011. Each of said patients was given an average of six doses of the vaccine that was given the name of HSPPC-96. The report said that 90 percent of the patients were still alive after six months and 30 percent, after a year. It goes without saying that the work which is rooted in this condition still has to be done. That being said, the potential is something that Stu Millheiser can observe.
Treatment is one of those ideas linked to glioblastoma research that is constantly being worked on. It seems as though treatment in general is one of the broadest areas to consider as well and the fact that there are so many details to consider speaks volumes. Stem cells have been put to use in the past, so the tissue from tumors should be utilized if there are incentives to consider. To me, this goes to show that the degree of potential will prove to be one of the greatest.
News-Medical posted an article that spoke about an experimental vaccine that could be used in order to help those who have this condition. It would entail a degree of tumor tissue, which is needed in order to make it impactful. As the article would go on to state, patients saw increased levels of survival in comparison to what they might have had with only standard methods of care. There is quite a bit to talk about when it comes to the phase 2 trial tied to this vaccine.
For those who are unfamiliar with glioblastoma, you may be curious as to what makes it so aggressive? The article said that the tumors progress at rapid paces and, because of this, treatment options have limited results. Of course, there are methods that can be taken up, the most common being standard invasive surgery followed by chemotherapy and radiation. However, the long-term results are hard to document, which can be said about conditions like ALS too. This means that more work will be done, as well as seen by the likes of Stuart Millheiser.
The phase 2 trial came into being and it included a total of 41 patients that had tumors in between 2007 and 2011. Each of said patients was given an average of six doses of the vaccine that was given the name of HSPPC-96. The report said that 90 percent of the patients were still alive after six months and 30 percent, after a year. It goes without saying that the work which is rooted in this condition still has to be done. That being said, the potential is something that Stu Millheiser can observe.
Treatment is one of those ideas linked to glioblastoma research that is constantly being worked on. It seems as though treatment in general is one of the broadest areas to consider as well and the fact that there are so many details to consider speaks volumes. Stem cells have been put to use in the past, so the tissue from tumors should be utilized if there are incentives to consider. To me, this goes to show that the degree of potential will prove to be one of the greatest.
About the Author:
For additional details about ALS and Stu Millheiser, overall, contact Stuart Millheiser now.. This article, Stuart Millheiser: What To Know About HSPPC-96 is available for free reprint.
0 Response to "Stuart Millheiser: What To Know About HSPPC-96"